

1 **Induction of an early IFN- γ cellular response and high plasma levels of SDF-1 α are**
2 **inversely associated with COVID-19 severity and residence in rural areas in Kenyan**
3 **patients**

4 **Short Title:** Early IFN- γ response and high SDF-1 α levels linked to Lower COVID-19
5 Severity in rural Kenyan patients

6 **Authors**

7 Perpetual Wanjiku ^{1*}, Benedict Orindi ¹, John Kimotho ¹, Shahin Sayed ², Reena Shah ²,
8 Mansoor Saleh ², Jedidah Mwacharo ¹, Christopher Maronga ³, Vivianne Olouch ², Ann
9 Karanu ², Jasmit Shah ⁴, Zaitun Nneka ², Lynette Isabella Ochola-Oyier ^{1 5}, Abdirahman I.
10 Abdi ^{1 5}, Susanna Dunachie ⁶, Philip Bejon ^{1 5}, Eunice Nduati ^{1 5}, Francis M. Ndungu ^{1 5*}.

11 **Affiliations**

12 ¹ Centre for Geographic Medicine Research (Coast), Kenya Medical Research Institute
13 (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya.

14 ² Aga Khan University Hospital, 3rd Parklands Avenue, Nairobi, Kenya.

15 ³ Nuffield Department of Population Health, Cancer Epidemiology Unit, University of
16 Oxford, Oxford, United Kingdom.

17 ⁴ Brain and Mind Institute and Department of Medicine, Aga Khan University, Nairobi,
18 Kenya.

19 ⁵ Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

20 ⁶ Nuffield Department of Medicine, Centre for Global Health Research, University of
21 Oxford, Oxford, United Kingdom.

22

23 * Corresponding authors

24 pwanjiku@kemri-wellcome.org (PW)

25 fdungu@kemri-wellcome.org (FMN)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Abstract**

27 **Introduction**

28 COVID-19 was less severe in Sub-Saharan Africa (SSA) compared with Europe and North
29 America. It is unclear whether these differences could be explained immunologically. Here
30 we determined the levels of *ex vivo* SARS-CoV-2 peptide-specific IFN- γ producing cells, and
31 levels of plasma cytokines and chemokines over the first month of COVID-19 diagnosis
32 among Kenyan COVID-19 patients from urban and rural areas.

33 **Methods**

34 Between June 2020 and August 2022, we recruited and longitudinally monitored 188
35 COVID-19 patients from two regions in Kenya, Nairobi (urban, n = 152) and Kilifi (rural, n =
36 36), with varying levels of disease severity – severe, mild/moderate, and asymptomatic. IFN-
37 γ secreting cells were enumerated at 0-, 7-, 14- and 28-days post diagnosis by an *ex vivo*
38 enzyme-linked immunospot (ELISpot) assay following *in vitro* stimulation of peripheral
39 blood mononuclear cells (PBMCs) with overlapping peptides from several SARS-CoV-2
40 proteins. A multiplexed binding assay was used to measure the levels of 22 plasma cytokines
41 and chemokines.

42 **Results**

43 Higher frequencies of IFN- γ -secreting cells against the SARS-CoV-2 spike peptides were
44 observed on the day of diagnosis among the asymptomatic compared to the patients with
45 severe COVID-19. Higher concentrations of 17 of the 22 cytokines and chemokines
46 measured were positively associated with severe disease, and in particular interleukin (IL)-8,
47 IL-18 and IL-1ra ($p < 0.0001$), while a lower concentration of SDF-1 α was associated with
48 severe disease ($p < 0.0001$). Concentrations of 8 and 16 cytokines and chemokines including
49 IL-18 were higher among Nairobi asymptomatic and mild patients compared to their

50 respective Kilifi counterparts. Conversely, the concentrations for SDF-1 α were higher in rural
51 Kilifi compared to Nairobi (p=0.012).

52 **Conclusion**

53 In Kenya, as seen elsewhere, pro-inflammatory cytokines and chemokines were associated
54 with severe COVID-19, while an early IFN- γ cellular response to overlapping SARS-CoV-2
55 spike peptides was associated with reduced risk of disease. Living in urban Nairobi
56 (compared with rural Kilifi) was associated with increased levels of pro-inflammatory
57 cytokines/chemokines.

58 **Keywords:** COVID-19, SARS-CoV-2, IFN- γ -secreting cells, cytokines, chemokines,
59 kinetics, Sub-Saharan Africa.

61 **Introduction**

62 Despite widespread transmission of SARS-CoV 2, SSA experienced a reduced burden of
63 severe coronavirus disease 2019 (COVID-19) and associated mortality than North America
64 and Europe (1). This observation is both puzzling (2) and paradoxical (3), because of the
65 relatively weaker and underfunded health systems in SSA. Some of the proposed, but still
66 unproven, explanations for the reduced burden of severe COVID-19 in SSA include under-
67 diagnosis of cases and mortality, a younger population (7), warmer climatic conditions with
68 outdoor living, high levels of pre-existing cross-protective antibodies and T-cells induced
69 from a high prevalence of infectious agents with SARS-CoV-2 like immune determinants,
70 and immune regulation associated with either prior BCG vaccination (5–11) or
71 chronic/repeated infections including helminths (12) and malaria (13). Like other viruses,
72 SARS-CoV-2 induces a plethora of inflammatory host responses, including cytokines and
73 chemokines (14), that play key roles in either protective immunity or immunopathology (15).
74 Notably, the pathogenesis of COVID-19 has been linked to dysregulated and excessive
75 cytokine and chemokine responses, upon SARS-CoV-2 infection (16). Numerous studies
76 have linked increased levels of cytokines and chemokines to severe COVID-19 and
77 associated mortality, including IL-1 β , IL-1ra, IL-2, IL-6, IL7, IL-8, IL-18, IFN- γ , TNF- α ,
78 IFN- γ -inducible protein 10 (IP-10), granulocyte macrophage-colony stimulating factor (GM-
79 CSF), monocyte chemoattractant protein-1 (MCP-1), and Macrophage inflammatory protein-
80 1 alpha (MIP-1- α) (17–24). Collectively called a “cytokine storm”, a dysregulated cytokine
81 response is implicated as the cause of the multiple organ failures and the acute respiratory
82 distress syndrome (ARDS), which characterise severe COVID-19 and associated fatalities
83 (25).

84 Published data show that the characteristic antibody response to SARS-CoV-2 infection,
85 where levels increase with time, viral loads and COVID-19 severity, were experienced in
86 Kenyan patients (26). Thus, there is no evidence of the primary acute antibody response
87 controlling the infection outcome. Aside from antibodies, T-cell responses can control
88 viremia, either directly by killing virus infected cells or indirectly by providing the relevant
89 co-stimulatory molecules for supporting antibody production by B cells (27). However, there
90 is a paucity of data on the cellular response to SARS-CoV-2 in Kenyan patients, and its
91 possible role in modulating disease severity. Furthermore, it is unclear whether the
92 differences in the rates of severe disease between urban and rural dwellers within SSA, as
93 well as between developed countries and SSA, could be explained immunologically. In this
94 study, we collected longitudinal blood samples from individuals from Nairobi (urban) and
95 Kilifi (rural) with varying degrees of COVID-19 severity (asymptomatic, mild/moderate and
96 severe) and compared levels of their *ex vivo* SARS-CoV-2 Spike peptide-specific IFN- γ
97 producing cells, and levels of plasma cytokines and chemokines over their first month of
98 COVID-19 diagnosis.

99

100 **Methods**

101 **Study design, setting and participants**

102 Participant sampling has been described previously (26). Briefly, we included 400 blood
103 samples from a longitudinal cohort study of 188 patients that aimed at understanding the
104 kinetics of naturally acquired immune responses to SARS-CoV-2 among COVID-19 patients
105 from two sites in Kenya: 1) The Aga Khan University Hospital (AKUH) in Nairobi, an urban
106 metropolitan academic medical Centre; and 2) Kilifi County Hospital, a community-based
107 government hospital serving a rural coastal region. The samples were collected during the
108 COVID-19 pandemic between June 2020 and August 2022. At the time of the study, SARS-
109 CoV-2 transmission in Nairobi was higher than in Kilifi (28). Participants were adults, aged
110 ≥ 18 years old, recruited within seven days of positive diagnosis of COVID-19 by RT-PCR
111 testing. Initial sampling was at day 0 (i.e., day of diagnosis). Follow-up and subsequent
112 samplings were done on days 7, 14 and 28 from a positive SARS-CoV-2 infection diagnosis.
113 We collected 20 mL of venous blood in sodium heparin vacutainer. Additionally, we
114 included residual longitudinal plasma samples from the AKUH biobank for cytokine and
115 chemokine measurements. These samples were collected from COVID-19 patients who
116 consented to this follow-up study on the day of diagnosis (i.e., day 0) and on day 28.

117 **COVID-19 severity classification**

118 We included patients from five COVID-19 severity groups of asymptomatic, mild, moderate,
119 severe, and critical as determined by clinicians at the time of diagnosis following the
120 National Institutes of Health (NIH, USA) guidelines(29). Asymptomatic patients were those
121 who tested positive for SARS-CoV-2 via RT-PCR but did not display any COVID-19
122 symptoms. Mild cases were SARS-CoV-2 positive and exhibited symptoms such as fever,
123 sore throat, cough, malaise, headache, muscle pain, vomiting, nausea, diarrhoea, anosmia, or

124 ageusia, without any signs of shortness of breath, dyspnea, or abnormal chest imaging.
125 Moderate cases tested positive for SARS-CoV-2 and showed evidence of lower respiratory
126 tract infection based on clinical examination or imaging, with an oxygen saturation (SpO₂) of
127 $\geq 94\%$ on room air. Severe cases were positive for SARS-CoV-2 with an SpO₂ of $< 94\%$ on
128 room air, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen
129 (PaO₂/FiO₂) < 300 mm Hg, a respiratory rate > 30 breaths/minute, and/or lung infiltrates
130 $> 50\%$. Critically ill patients were positive for SARS-CoV-2 and experienced respiratory
131 failure, septic shock, and/or multiple organ dysfunction syndrome. Due to the small numbers
132 in the moderate and critical groups, mild cases were lumped together with moderate
133 (mild/moderate), whilst critical were grouped with severe ones (severe). Thus, we studied
134 immune responses among three COVID-19 patient groups: asymptomatic, mild/moderate and
135 severe.

136 **Procedures**

137 **Plasma separation and PBMC isolation**

138 Plasma was separated by centrifuging the tubes at 440 g for 10 minutes using an Eppendorf
139 5810R centrifuge, aliquoted in 2 mL microcentrifuge tubes, and immediately stored in -80°C
140 freezers until the time for laboratory analysis. PBMCs were isolated from the remaining
141 blood component using density gradient centrifugation media (LymphoprepTM (1.077 g/ml,
142 Stem Cell Technologies), aliquoted to 1.8 mL cryovials, and stored in -196°C liquid nitrogen
143 tanks until usage. Plasma and PBMC samples from AKUH were transported in dry ice and
144 liquid nitrogen respectively, to the KEMRI–Wellcome Trust Research Programme
145 laboratories in Kilifi and stored appropriately for laboratory analyses. Prior to use, PBMCs
146 were thawed and rested at 37°C , 5% CO₂ for 15–16 hours. PBMC counting was done using
147 Vi-CELL XR Cell Viability Analyser or CountessTM Cell Counting Chamber Slides (Thermo
148 Scientific) before assay setup.

149 **SARS-CoV-2 synthetic peptides pools for ELISpot measurements**

150 A total of 641 peptides (15–18-mers with a ten amino acid overlap) were pooled into ten
151 peptide pools, spanning different regions of the virus. The pools covered: the spike protein
152 region (S1: positions 1–93 and S2: positions 94–178), membrane protein (M: positions 1–31),
153 nucleocapsid protein (NP: positions 1–55), non-structural proteins (NSP 3B: positions 207–
154 306, NSP 3C: position 307–379, NSP 12B: positions 665–729 and NSP 15–16: positions 886–
155 972) and Open Reading Frame (ORF3: positions 1–37 and ORF8: positions 1–15). These
156 peptides (which were synthesised by Mimotopes Pty Ltd and a kind donation from Professor
157 Susanna Dunachie’s laboratory, Oxford University) were used to stimulate PBMCs for *ex*
158 *vivo* IFN- γ ELISpot assay. The peptide sequences and pooling details are provided in Table
159 S1.

160 **Interferon gamma ELISpot assay**

161 To quantify *the ex vivo* interferon gamma (IFN- γ) cellular response to overlapping SARS-
162 CoV-2 peptides from different proteins, we stimulated PBMC with synthetic peptides pools
163 through an *in vitro* IFN- γ ELISpot assay, as previously described (30). Briefly, 5 μ g/ml of
164 anti- human IFN- γ antibody clone 1-D1K (Mabtech, AB, Sweden) was used to coat
165 Multiscreen-I 96 ELISpot plates overnight. Individual’s PBMC were plated in duplicates at
166 200,000 cells per well for each specific protein, based on pre-prepared plate templates.
167 Peptide pools were then added at a final concentration of 2 μ g/mL per wells and incubated
168 for 16–18 hours at 37°C, 5% CO₂, 95% humidity. Concanavalin A (ConA; Sigma) was used
169 as the positive control at a final concentration of 5 μ g/mL per well, while dimethyl sulfoxide
170 (DMSO; Sigma), which was a constituent of the diluent for the peptides and Con A was used
171 at a similar concentration to peptides to serve as the negative control. IFN- γ secreting cells
172 were then detected using an anti-human IFN- γ biotinylated antibody clone 7-B6-1 (Mabtech)
173 at 1 μ g/mL and an incubation for 2–4 hours. Thereafter, streptavidin alkaline phosphatase

174 antibody (Mabtech) was added at 1 µg/mL and incubated for 1–2 hours, and the IFN-γ spots
175 then developed using 1-Step™ NBT/BCI (nitro blue tetrazolium/5-bromo-4-chloro-3-
176 phosphatase) substrate (Thermo Scientific) during a 7-minute incubation in the dark. The
177 enzyme-substrate reaction was stopped by rinsing the plate 3 times under running tap water.
178 Plates were then airdried for at least 2 days on an open lab bench, and spots enumerated on an
179 AID ELISpot Reader version 4.0. Results are hereby reported as spot-forming units
180 (SFU)/10⁶ PBMC after subtracting the background (mean SFU from negative control
181 wells). Data from failed individual PBMC tests, defined here as either, an excessive
182 background where the negative control wells had >80 SFU/10⁶ PBMCs, or a positive
183 control well with an average of <100 SFU/10⁶ PBMCs (too few), were excluded. We also
184 applied the ELISpot assay limit of detection of 10 SFU/10⁶ PBMCs, with all wells having
185 values <10 SFU/10⁶ PBMCs replaced with 5 SFU/10⁶ PBMCs. For the participants who
186 did not have enough PBMC to be tested against all the peptide pools, we prioritised
187 measurements against pools from S1, S2, NP and M proteins. Data are reported only for the
188 individuals whose PBMC were tested against all the available peptide pools for each specific
189 protein segment. We summed the responses from the different pools of the same protein
190 segment, which resulted in different sample sizes for different proteins as follows: spike (171
191 samples for S1, S2), NP (162 samples), M (136 samples), NSPs (100 samples for NSP 3B,
192 NSP 3C, NSP 12B and NSP 15 -16) and ORF (90 samples for ORF 3 and ORF 8) Table S2.

193 **Luminex assay**

194 Plasma concentrations of 22 cytokines and chemokines were measured using a Human
195 ProcartaPlex™ Human Panel 1A (Thermo Fisher Scientific, Cat. No. EPX010-12010-901,
196 Lot number 316776-000), which consisted of: a) Th1/Th2 specific cytokines: GM-CSF, IFN-
197 γ, IL-1β, IL-2, IL-6, IL-8, IL-18, TNF-α, IL-9, IL-21; b) Pro-Inflammatory cytokines: IFN-α,
198 IL-1α, IL-1ra, IL-7, TNF-β; and c) Chemokines: Eotaxin, GRO-α, IP-10, MCP-1, MIP-1α,

199 MIP-1 β , SDF-1 α , according to the manufacturer's instructions. Briefly, 1x capture magnetic
200 beads were added to the plates, and unbound beads were then washed away with 1X wash
201 buffer. Plasma samples were thawed and diluted at 1:2 with 1X universal assay buffer (UAB)
202 before addition to the plates. Standards from the kit at 4-fold serial dilutions of 1:5, 1:20,
203 1:80, 1:320, 1:1280, 1:5120, 1:20480 as well as a blank (UAB), were also added. The plates
204 were then incubated on a shaker at 600 rpm for 2 hours at room temperature. After
205 incubation, contents were discarded, plates washed, and 1X biotinylated detection antibody
206 added. The plates were then incubated for 30 minutes on an Eppendorf Thermomixer
207 Comfort shaker at room temperature. The plates were then washed, and 1X Streptavidin-PE
208 added and incubated for 30 minutes on an Eppendorf Thermomixer Comfort shaker at room
209 temperature, the plates were then washed before adding 1X reading buffer for 5 minutes on
210 an Eppendorf Thermomixer Comfort shaker at room temperature. All wash steps were
211 performed on an Invitrogen hand-held magnetic plate washer. Data were acquired on the
212 Magpix systems multiplex Luminex machine and concentrations (pg/mL) of the samples
213 calculated in Belysa® Immunoassay Curve Fitting software version 1.1.0 (31) using a 5- or
214 4-parameter logistic standard curve generated from standards of known concentration.

215 **Statistical analysis**

216 For the ELISpot data, time point specific geometric means (GMs) of IFN- γ secreting cells for
217 each of the different SARS-COV-2 peptides pools were calculated for each severity group
218 and geographical location. For each peptide, variations in ELISpot responses were compared
219 using a linear mixed effects model on log-transformed PBMCs values with patient as a
220 random effect, and time (i.e., day of sampling), severity group and time-by-severity group
221 interaction term as fixed effects (32), followed by Tukey's multiple comparisons. Within
222 each severity group, differences between geographic locations were compared using Kruskal

223 Wallis paired with a Dunn's multiple comparisons. This analysis set was restricted to 59
224 patients who had PBMC samples.

225 Cytokine and chemokine data were first normalised to have a zero mean and a standard
226 deviation of one, and cross-correlations among the cytokines determined using Pearson
227 correlations and principal component analysis (PCA). Principal components (PCs) were
228 extracted based on scree-plot, variance explained and the interpretability of the components.

229 Next, the non-normalised cytokine and chemokine data were log-transformed and fitted into
230 linear mixed effects regression models with age, sex, day of sampling, location or disease
231 severity as fixed effects and patient as a random effect. Interactions were explored and
232 separate models fitted where necessary. For location comparisons, severe and moderate
233 COVID-19 cases were excluded as these categories were only present in the Nairobi data.

234 Results from the regression models were presented using heat maps, in which the effect size
235 (i.e., coefficient) determined the density of colour-shading for each square. TNF- β data were
236 excluded from the analyses as only one patient had a measurable concentration. Thus, we
237 analysed 21 cytokines from all 188 patients. Analyses were performed using R version 4.3.0
238 (33). The factoextra package (34) was used for PCA. For visualisations, the pheatmap (35)
239 and ggplot2 (36) packages and GraphPad Prism Software version 10.1.2 (37) were used.

240 **Ethical approval**

241 The study obtained ethical approval from the Kenya Medical Research Institute's Scientific
242 and Ethics Review Unit (KEMRI SERU; protocol no. 4081) and the Aga Khan University,
243 Nairobi, Institutional Ethics Review Committee (protocol no. 2020 IERC-135 V2). Written
244 informed consent was obtained from all willing patients before their enrolment into the study.

245

246 Results

247 Participant baseline characteristics

248 Using the NIH clinical guidelines for grading COVID-19 severity of 188 patients, 27 (14%)
249 were asymptomatic, 75 (40%) were mild/moderate and 86 (46%) were severe cases.
250 Collectively, the 188 patients contributed 400 blood samples collected over the first month of
251 diagnosis: day 0 (187 samples), day 7 (50 samples), day 14 (53 samples), and day 28 (110
252 samples). Fewer samples were collected on days 7 and 14 mainly due to design; that is,
253 residual longitudinal plasma samples from AKUH biobank were only collected in day 0 and
254 day 28. Of the 188 patients, 129 (69%) were male, 36 (19%) were from rural Kilifi and 152
255 (81%) from urban Nairobi (Table 1). Their median age at recruitment was 48 years (IQR 37–
256 58), with disease severity increasing with age. All 86 patients with severe COVID-19 were
257 from Nairobi as we were unable to recruit severe patients in Kilifi. Underlying comorbidities
258 such as diabetes, HIV/AIDS, and hypertension were prevalent among the mild/moderate and
259 severe COVID-19 groups. Two participants with severe disease died on day 7 and 28
260 respectively (Table 1).

261 **Table 1.** Participant demographic and clinical characteristics[†]

Characteristic	Asymptomatic (n = 27)	Mild/Moderate (n = 75)	Severe (n = 86)
Median age at recruitment (IQR), years	40 (33, 55)	46 (35, 54)	53 (43, 60)
Male sex	15 (56%)	46 (61%)	68 (79%)
Location			
Kilifi	21 (78%)	15 (20%)	0

Characteristic	Asymptomatic (n = 27)	Mild/Moderate (n = 75)	Severe (n = 86)
Nairobi	6 (22%)	60 (80%)	86 (100%)
Comorbidities			
Diabetic	1 (7%)	28 (42%)	47 (63%)
Hypertensive	0	15 (22%)	33 (44%)
HIV positive	0	5 (8%)	4 (5%)
Had COPD	0	0	1 (1%)
Had Renal disease	0	0	2 (3%)
Had heart disease	0	0	6 (8%)
Patient management			
Were hospital admissions	0	56 (84%)	75 (100%)
In intensive care unit	0	4 (6.0%)	15 (20%)
Clinical Outcome, died	0	0	2 (3%)

262 † Data are median (IQR) or number (%); COPD if Chronic obstructive pulmonary disease.

263 Kinetics and frequencies of *ex vivo* IFN- γ secreting cells by

264 COVID-19 severity and geographical location

265 Kinetics and levels of IFN- γ secreting cell responses were assessed in a subset of 59
266 participants with PBMC samples, contributing 172 samples. At day 0, the frequency of IFN- γ
267 secreting cells to overlapping SARS-CoV-2 spike peptide was significantly higher in
268 asymptomatic patients compared to severe patients (GMs: 117 [95% CI 71–194] vs 32 [95%
269 CI 8–76]; p=0.0366) (Figure 1a, Table S3). For the IFN- γ secreting cells specific to

270 overlapping M peptides, severe patients exhibited significantly higher levels at day 7 than
271 mild/moderate patients (GMs: 90 [95% CI 37–217] vs 19 [95% CI 10–39]; $p=0.0180$; Figure
272 1b, Table S3). We did not observe any significant differences in the frequencies of IFN- γ
273 secreting cell responses to NP, NSPs, and ORFs overlapping peptides (Figure 1c–e, Table
274 S3). For all five SARS-CoV-2 peptides we observed temporal differences in IFN- γ secreting
275 cells within each COVID-19 severity group (Figure 1, Table S3). Spike peptide: In the
276 asymptomatic group, IFN- γ secreting cells were significantly elevated on day 7 than on day
277 14 (GMs: 161 [95% CI 86–301] vs 92 [95% CI 44–189]; $p=0.0039$) and day 28 (102 [95% CI
278 49–209]; $p=0.0042$). For the mild/moderate group, levels significantly increased from 86
279 (95% CI 53–138) on day 7 to 142 (95% CI 78–257) on day 14 ($p=0.0403$). In the severe
280 group, significantly higher levels were observed on day 7 (70 [95% CI 29–165]; $p=0.0381$),
281 day 14 (117 [95% CI 52–260]; $p=0.0058$), and day 28 (108 [95% CI 33–348]; $p=0.0037$)
282 relative to day 0 (23 95% CI 7–76).

283 M Peptide: In the asymptomatic patients, IFN- γ secreting cells were significantly higher on
284 day 14 (89 [95% CI 30–258]) compared to day 0 (GMs: 28 [95% CI 13–59]; $p=0.0364$) and
285 day 7 (GMs: 48 [95% CI 18–129]; $p=0.0297$). In the mild/moderate group, day 14 levels
286 were significantly higher compared to day 0 ($p=0.0039$), day 7 ($p<0.0001$), and day 28
287 ($p=0.002$). Additionally, day 28 levels were significantly higher than day 7 ($p=0.0049$). No
288 significant differences were observed between timepoints in the severe group.

289 NP Peptide: Among the asymptomatic group, a significant decline was observed from day 7
290 (71 [95% CI 33–153]) to day 28 (47 [95% CI 24–88]; $p=0.0035$). In the mild/moderate
291 group, IFN- γ secreting cell levels were significantly higher on day 14 (GMs: 67 [95% CI 34–
292 130]) compared to day 0 (GMs: 35 [95% CI 14–83]; $p=0.0037$), day 7 (GMs: 44 [95% CI 26–
293 73]; $p=0.0178$), and day 28 (GMs: 47 [95% CI 24–91]; $p=0.0003$). No significant differences
294 were observed between timepoints in the severe group. For NSP peptide: a significant decline

295 in IFN- γ secreting cells was observed within the mild/moderate group from 80 (95% CI 33–
296 194) at day 14 to 28 (95% CI 7–106) at day 28 ($p=0.0316$). For ORF peptide: a significant
297 increase in IFN- γ secreting cells was observed in the mild/moderate group between day 0 (14
298 [95% CI 4–43]) and day 7 (GMs: 38 [95% CI 16–85]; $p=0.0242$).

299 **Figure 1. Induction of a higher IFN-gamma cellular response to Spike protein on day of**
300 **diagnosis is associated with asymptomatic infection.**

301 Frequencies of ex-vivo IFN- γ secreting cells against SARS-CoV-2 peptide pools spanning (a)
302 spike protein, (b) M protein, c NP protein, (d) NSP proteins and (e) ORF proteins. Bars
303 represent geometric mean and 95% CI.

304 Linear mixed effects model with Tukey’s multiple comparisons, was used, * $P < 0.05$.

305 Number of samples analysed for: spike responses = 171, M responses = 136, NP responses =
306 162, NSP responses = 100 and ORF responses = 90.

307

308 We also assessed whether there were differences in IFN- γ secreting cell responses by location
309 (urban Nairobi and rural Kilifi) among asymptomatic and mild patients. Relative to Nairobi,
310 significantly higher levels of IFN- γ secreting cell responses to the SARS-CoV-2 spike
311 peptide (218 [95% CI 125–381] vs 56 [95% CI 28–110]; $p=0.0057$; Figure 2a) and NP
312 peptide (94 [95% CI 51–169] vs 19 [95% CI 8–48; $p=0.0171$; Figure 2c) were observed
313 among the asymptomatic patients in Kilifi on day 0. There were no significant differences
314 between Kilifi and Nairobi in the IFN- γ secreting cell responses to overlapping peptides for
315 the M protein for the asymptomatic patients (Figure 2b), nor for the spike, or NP, and or M
316 peptides among mild patients (Figure 2d–f). Data for severe patients are shown for Nairobi
317 participants only (Figure 2g–i), as we were unable to recruit severe patients in Kilifi.

318 **Figure 2. Induction of a higher IFN- γ cellular response on the day of diagnosis is**
319 **associated with Kilifi participants.**

320 Comparison of IFN- γ cellular responses between Kilifi and Nairobi COVID-19 patients with:
321 asymptomatic disease for (a) Spike protein, (b) M protein, (c) NP protein; Mild disease for
322 (d) Spike protein, (e) M protein, (f) NP protein; and Severe disease for (g) Spike protein, (h) M
323 protein, (i) NP protein. Kilifi didn't have severe patients.
324 Bars represent geometric mean and 95% CI. Kruskal–Wallis one-way ANOVA, with Dunn's
325 multiple comparisons test, was performed. * $P < 0.05$, ** $P < 0.01$.

326

327 **Kinetics of cytokine and chemokine responses across COVID-19** 328 **severity groups and geographical location**

329 Asymptomatic patients consistently showed elevated levels of SDF-1 α at all time-points, but
330 lower levels of all the other cytokines and chemokines measured and no detectable levels of
331 IL-9 (Figure 3a). Similarly, for mild/moderate patients, high levels of SDF-1 α (Figure 3b),
332 were observed at all timepoints whereas other cytokines and chemokines were secreted at low
333 to intermediate levels. High cytokine and chemokines levels were seen among the severe
334 patients with IL-1 β , IL-6, IL-2, IFN- γ , GM-CSF, IFN- α , IL-7 and GRO- α decreasing over
335 time, while MIP-1 α , MIP-1 β , MCP-1, and SDF-1 α increased with time. Levels for IL1-ra, and
336 IL-9 were similar at all the time points (Figure 3c).

337 **Figure 3. Kinetics of Cytokine and Chemokine Concentrations in COVID-19 Patients.**

338 Mean of log₁₀-transformed cytokine/chemokine concentrations plotted over time for (a)
339 Asymptomatic participants, (b) Mild/Moderate participants, and (c) Severe participants. * -
340 Levels for all participants were below detectable levels.

341

342 We compared asymptomatic against mild/moderate and severe participants to evaluate
343 differences among the clinical phenotypes. Mild/moderate participants had significantly
344 higher levels of IL-18, IL-8, IL-1ra, IL-6, GM-CSF, IP-10, MCP-1, TNF- α , MIP-1 α , IFN- γ ,

345 IL-2, IL-7, IL-1 β , IL-9, Eotaxin and IFN- α than asymptomatic patients. The largest effect
346 sizes were observed with IL-18 (1.107, $p < 0.0001$), IL-8 (1.105, $p < 0.0001$) and IL-1ra,
347 (0.672, $p = 0.013$). On the contrary, levels for SDF-1 α were significantly reduced among the
348 mild/moderate patients relative to the asymptomatic (effect size -0.182, $p < 0.0001$) (Figure 4).
349 Severe participants had significantly higher levels for cytokines (IL-8, IL-18, IL-1ra, IL-6,
350 IP-10, MIP-1 α , TNF- α , IL-9, IFN- γ , GM-CSF, IL-7, IL-1 β , MCP-1, IL-2, GRO- α , Eotaxin
351 and IFN- α) compared to asymptomatic cases, except for IL-1a, IL-21 and MIP-1 β which had
352 similar levels, and SDF-1 α (effect size -0.195, $p < 0.0001$), which was significantly reduced.
353 The largest effect size was observed in IL-8 (1.754, $p < 0.0001$), IL-18 (1.666, $p < 0.0001$) and
354 IL-1ra (1.197, $p < 0.0001$) (Figure 4).
355 For asymptomatic individuals, the cytokines and chemokine levels for IL-6, MIP-1 α , IL-18,
356 GRO- α , IL-2, IL-8, TNF- α and GM-CSF were significantly higher among Nairobi than Kilifi
357 patients. Comparisons for IL-6 (1.139, $p < 0.0001$), MIP-1a (1.093, $p = 0.004$) and IL-18
358 (1.025, $p = 0.002$) had the largest effect sizes (Figure 4). For mild patients, all cytokines (IL-8,
359 IL-18, IL-1ra, MIP-1 α , IL-6, IP-10, IFN- γ , TNF- α , MCP-1, GM-CSF, IL-9, IL-1 β , Eotaxin,
360 IL-7, MIP-1 β , and IFN- α) were significantly higher among Nairobi patients in comparison to
361 Kilifi patients except for GRO- α , IL-1 α , IL-2 and IL-21 which were similar. Notably, the
362 largest effect size for these comparisons was observed for IL-8 (1.69, $p < 0.0001$), IL-18
363 (1.634, $p < 0.0001$) and IL-1ra (1.355, $p < 0.001$). On the other hand, SDF-1 α (effect size -
364 0.161, $p = 0.017$) was significantly lower in Nairobi than in Kilifi patients.

365 **Figure 4. Higher Cytokine and Chemokine concentrations in Asymptomatic and Mild**
366 **Patients from Nairobi Compared to Kilifi, and in Mild/Moderate and Severe Patients**
367 **Compared to Asymptomatic Individuals.**

368 ns – not-significant, p value > 0.05 , empty means it was significant at $p < 0.05$ - < 0.0001 . * -
369 Levels for all participants were below detectable levels.

370

371

372 **Principal component analysis**

373 The concentrations of the majority of the 21 cytokines and chemokines were positively
374 correlated with each other. However, the levels of SDF-1 α were negatively correlated with
375 those of IL-2, IP-10, IL-7, IFN- γ , GM-CSF, and IL-18 (Figure S1). We retained the first three
376 principal components from a principal component analysis, accounting for 62% of the total
377 variability in the 21 cytokines and chemokines (Figure S2a). IL-9, MIP-1 α , TNF- α , MCP-1,
378 MIP-1 β , IL1-ra, IL-6, IL-1 β , GRO- α and IL-8 were the most strongly associated with the first
379 PC. The second PC was most strongly associated with IP-10, IFN- γ , GM-CSF, IL-2, IL-18,
380 IL-7, IFN- α , Eotaxin and SDF-1 α . The third PC was associated with IL-1 α and IL-21 (Figure
381 S3). There was no clear separation among the mild/moderate and severe groups. However,
382 data points for the asymptomatic participants clustered together demonstrating a much-
383 reduced diversity of cytokine and chemokine levels than the other groups (Figure 5), and
384 median PC scores did not change over the first month (Figure S2b).

385 **Figure 5. Scatter plot by Severity at baseline.**

386 **(a) PC1 vs PC2; (b) PC2 vs PC3**

387

388 Among the symptomatic groups (mild/moderate/severe), a steady decline of all the PCs over
389 one month was observed, with a steep decline occurring between day 0 and day 7 (Figure
390 S2c). There was no apparent difference of the cytokine and chemokine responses between
391 asymptomatic participants from Kilifi and Nairobi (Figure S4a). For mild cases, Kilifi
392 patients clustered together, although there was a slight overlap with Nairobi participants
393 (Figure S4b). Using biplots, there was no apparent difference between asymptomatic and
394 mild Kilifi patients (Figure S4c). For Nairobi, clinical phenotypes were asymptomatic, mild,
395 moderate, and severe. We combined the mild and moderate, and observed no clear difference

396 between the mild/moderate and severe groups, while the few asymptomatic participants

397 seemed to cluster together (Figure S4d).

398

399

400

401 **Discussion and conclusion**

402 In this study, we measured associations between the acute IFN- γ cellular, and 22 cytokine
403 and chemokine, immune response to SARS-CoV-2 (within a month of diagnosis) with
404 COVID-19 severity and possible modulation by differential environmental exposures in
405 urban and rural areas in Kenya.

406 As had been seen in earlier reports from Singapore, Netherlands, and Italy, which associated
407 increased IFN- γ secreting cells measured by ELISpot assay in the early phase of infection
408 with milder disease (38–40), we found that higher frequencies of an early IFN- γ cellular
409 response to SARS-CoV-2 spike overlapping peptides was associated with asymptomatic,
410 compared to severe SARS-CoV-2 infection outcomes. This observation would suggest either:
411 1) that the IFN- γ cellular response contribute to protection against disease progression, or 2)
412 that developing severe COVID-19 depresses this response. The latter interpretation may be
413 supported by previous reports from China and USA reporting correlations of an early
414 induction of increased basal T-cell specific responses (CD4⁺ and CD8⁺ T) in COVID-19
415 patients with mild disease, which was suppressed among their severely sick counterparts
416 (41,42).

417 Whilst the concentrations of the pro-inflammatory cytokines and chemokines IL-6, IL-I β ,
418 GRO- α , IFN- γ , GM-CSF, IFN- α , IL-7 and IL-2 in severe patients declined to basal levels at
419 day 28 from day of diagnosis, we found that the concentrations for the chemokines MIP-1 α ,
420 MIP-I β , MCP-1, and SDF-1 α were increasing with time. This is to be expected as cytokines
421 and chemokines play different roles and at different times of the immune response to
422 infection. MIP-1 α , MCP-1 and MIP-I β are chemoattractant and play key roles in the
423 recruitments of leukocytes such as monocytes, T-cells, and neutrophil to the sites of infection
424 (43,44). Similarly increasing kinetics for MIP-1 α and MCP-1 in severe and fatal patients
425 were reported in Norway and China, respectively (45,46). Notably, we found that higher

426 concentrations of SDF-1 α were associated with asymptomatic individuals, hinting at a
427 potential protective role from severe disease progression. SDF-1 α (CXCL12), is a
428 chemokine involved in the recruitment of T-cells (47), CD34+ hematopoietic stem/progenitor
429 cells (48), lymphocytes and monocytes (49) to the site of infection further enhancing
430 inflammation. In contrast, studies from China and Bulgaria did not observe significant
431 differences in SDF-1 α levels among asymptomatic, mild, moderate, severe or fatal cases
432 (18,46,50). However, others have also implicated SDF-1 α in disease severity based on
433 genetic association studies in a single-centre study (51), although this finding was not
434 corroborated in multi-centre genome-wide association studies (52). SDF-1 α may aid in the
435 timely recruitment of T and other cells (47), to the sites of infection, enhancing viral
436 elimination, reduction in inflammation, and promotion of recovery.

437 We demonstrate that elevated levels of eighteen cytokines and chemokines were associated
438 with severe COVID-19, in agreement with previous reports linking them to severe lung
439 injury and ARDS (17–22,53). However, the associations with IL-8, IL-18 and IL-1ra, had the
440 strongest effect sizes in the current study. IL-8, has been implicated in the activation and
441 recruitment of neutrophils to the site of infection, thereby promoting inflammation (54). IL-
442 18 amplifies the immune response by inducing the production of IFN- γ by T-cells and natural
443 killer cells (55). Thus, IL-8 and IL-18 could amplify the excessive inflammation that
444 characterises severe COVID-19. On the contrary, IL1-ra is known to suppress the production
445 of proinflammatory cytokines such as IL-1 and TNF- α (56), and probably helps mitigate the
446 effects of excessive inflammation, thus reducing tissue damage and associated mortality.

447 In parallel to the reduced rates of severe COVID-19 and associated deaths in SSA relative to
448 North America and Europe, we and others have suggested higher rates of severe COVID-19
449 in cities compared to rural areas in SSA (28). Whilst this difference could be explained by
450 higher levels of SARS-CoV-2 transmission in busy metropolitan cities, or by more complete

451 reporting of cases (28,57,58), we wondered whether there were also plausible biological
452 explanations. We compared inflammatory cytokine and chemokine levels, and found that the
453 asymptomatic patients from Nairobi had higher levels of 8 cytokines and chemokines than
454 their asymptomatic counterparts from Kilifi, with IL-6, IL-18 and MIP-1 α , having the
455 strongest associations. Similarly, levels of 16 cytokines and chemokines were higher among
456 mild- Nairobi, than Kilifi, COVID-19 patients with IL-8, IL-18 and IL-1ra being the most
457 differentially secreted. Moreover, the basal frequencies of IFN- γ secreting cells in
458 asymptomatic patients from Nairobi, relative to those of their Kilifi counterparts, were
459 reduced. Collectively, these findings would suggest that the immune response to SARS-CoV-
460 2 is less inflammatory among residents of rural areas (59).

461 Our study was faced with a few limitations. Firstly, our data are incomplete for some of the
462 patients due to missed follow-ups, or due to unavailability of adequate numbers of PBMCs to
463 quantify IFN- γ cellular responses to the full spectrum of the peptide pools corresponding to
464 all the different SARS-CoV-2 proteins. However, our analyses are assumed valid under the
465 missing at random mechanism given the likelihood approach (60). Secondly, we had
466 difficulties recruiting asymptomatic patients in Nairobi and were unable to recruit severe
467 cases in Kilifi and thus the sample size is relatively small.

468 In conclusion, although severe disease was rare in Kenya, the inflammatory cytokine profile
469 in patients with severe COVID is similar to that of North American and European severe
470 COVID-19 patients. However, just like the early IFN- γ secreting cellular response, increased
471 levels of the chemokine, SDF-1 α , were associated with asymptomatic SARS-CoV-2
472 infection, suggesting a potential role of these responses in protection against disease
473 progression. Finally, the differential cytokine and chemokine, and IFN- γ cellular responses
474 between urban Nairobi and rural Kilifi patients suggest a plausible biological explanation for
475 the increased frequency of severe COVID-19 in African SSA cities relative to rural areas.

476 Together, these findings provide insights into potentially COVID-19 protective immune
477 responses, and their modulation by differential environmental exposures. Nonetheless,
478 additional studies are required to extend and replicate these important findings as they could
479 inform future control of COVID-19 and empower the control of similar pandemics.

480

481

482 **Acknowledgments**

483 We thank the field workers, laboratory staff and healthcare workers involved in the

484 longitudinal blood sampling. We appreciate all the study participants.

485

486 **References**

- 487 1. Cabore JW, Karamagi HC, Kipruto HK, Mungatu JK, Asamani JA, Droti B, et al. COVID-
488 19 in the 47 countries of the WHO African region: a modelling analysis of past trends and
489 future patterns. *Lancet Glob Health*. 2022 Aug;10(8):e1099–114.
- 490 2. Maeda JM, Nkengasong JN. The puzzle of the COVID-19 pandemic in Africa. *Science*.
491 2021 Jan;371(6524):27–8.
- 492 3. Osayomi T, Adeleke R, Akpoterai LE, Fatayo OC, Ayanda JT, Moyin-Jesu J, et al. A
493 Geographical Analysis of the African COVID-19 Paradox: Putting the Poverty-as-a-
494 Vaccine Hypothesis to the Test. *Earth Syst Environ*. 2021 Sep 1;5(3):799–810.
- 495 4. Diop BZ, Ngom M, Poug ue Biyong C, Poug ue Biyong JN. The relatively young and rural
496 population may limit the spread and severity of COVID-19 in Africa: a modelling study.
497 *BMJ Glob Health*. 2020 May;5(5):e002699.
- 498 5. Wamai RG, Hirsch JL, Van Damme W, Alnwick D, Bailey RC, Hodgins S, et al. What
499 Could Explain the Lower COVID-19 Burden in Africa despite Considerable Circulation of
500 the SARS-CoV-2 Virus? *Int J Environ Res Public Health*. 2021 Aug 16;18(16):8638.
- 501 6. Ashworth J, Mathie D, Scott F, Mahendran Y, Woolhouse M, Stoevesandt O, et al. Peptide
502 microarray IgM and IgG screening of pre-SARS-CoV-2 human serum samples from
503 Zimbabwe for reactivity with peptides from all seven human coronaviruses: a cross-
504 sectional study. *Lancet Microbe*. 2023 Apr 1;4(4):e215–27.
- 505 7. Braun J, Loyal L, Frensch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-
506 reactive T cells in healthy donors and patients with COVID-19. *Nature*. 2020 Nov
507 12;587(7833):270–4.

- 508 8. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-
509 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
510 Nature. 2020 Aug;584(7821):457–62.
- 511 9. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of
512 T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
513 Unexposed Individuals. Cell. 2020 Jun 25;181(7):1489-1501.e15.
- 514 10. Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al.
515 Phenotype and kinetics of SARS-CoV-2–specific T cells in COVID-19 patients with acute
516 respiratory distress syndrome. Sci Immunol. 2020 Jun 26;5(48):eabd2071.
- 517 11. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and
518 cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020 Oct
519 2;370(6512):89–94.
- 520 12. Naidoo P, Ghazi T, Chuturgoon AA, Naidoo RN, Ramsuran V, Mpaka-Mbatha MN,
521 et al. SARS-CoV-2 and helminth co-infections, and environmental pollution exposure: An
522 epidemiological and immunological perspective. Environ Int. 2021 Nov 1;156:106695.
- 523 13. Anyanwu MU. The association between malaria prevalence and COVID-19 mortality.
524 BMC Infect Dis. 2021 Sep 19;21(1):975.
- 525 14. Mogensen TH, Paludan SR. Virus-cell interactions: impact on cytokine production,
526 immune evasion and tumor growth. Eur Cytokine Netw. 2001;12(3):382–90.
- 527 15. Mogensen TH, Paludan SR. Molecular Pathways in Virus-Induced Cytokine
528 Production. Microbiol Mol Biol Rev. 2001 Mar;65(1):131.

- 529 16. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in
530 COVID-19. *J Infect.* 2020 Jun;80(6):607–13.
- 531 17. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
532 infected with 2019 novel coronavirus in Wuhan, China. *The Lancet.* 2020 Feb
533 15;395(10223):497–506.
- 534 18. Chi Y, Ge Y, Wu B, Zhang W, Wu T, Wen T, et al. Serum Cytokine and Chemokine
535 Profile in Relation to the Severity of Coronavirus Disease 2019 in China. *J Infect Dis.*
536 2020 Aug 4;222(5):746–54.
- 537 19. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune
538 Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect*
539 *Dis Off Publ Infect Dis Soc Am.* 2020 Jul 28;71(15):762–8.
- 540 20. Trifonova I, Ngoc K, Nikolova M, Emilova R, Todorova Y, Gladnishka T, et al.
541 Patterns of cytokine and chemokine expression in peripheral blood of patients with
542 COVID-19 associated with disease severity. *Int J Immunopathol Pharmacol.* 2023
543 Dec;37:039463202311636.
- 544 21. Ndoricyimpaye EL, Van Snick J, Robert R, Bikorimana E, Majyambere O,
545 Mukantwari E, et al. Cytokine Kinetics during Progression of COVID-19 in Rwanda
546 Patients: Could IL-9/IFN γ Ratio Predict Disease Severity? *Int J Mol Sci.* 2023 Jul
547 31;24(15):12272.
- 548 22. Ling L, Chen Z, Lui G, Wong CK, Wong WT, Ng RWY, et al. Longitudinal Cytokine
549 Profile in Patients With Mild to Critical COVID-19. *Front Immunol [Internet].* 2021 Dec 6
550 [cited 2024 Apr 19];12. Available from:

- 551 <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.763292/ful>
- 552 1
- 553 23. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of
- 554 lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2
- 555 infected patients. *eBioMedicine* [Internet]. 2020 May 1 [cited 2024 Jul 18];55. Available
- 556 from: [https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964\(20\)30138-](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30138-9/fulltext)
- 557 [9/fulltext](https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30138-9/fulltext)
- 558 24. Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, Liew F, Russell CD, Moore
- 559 SC, et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for
- 560 GM-CSF in severe COVID-19. *Sci Immunol*. 2021 Mar 10;6(57):eabg9873.
- 561 25. Darif D, Hammi I, Kihel A, Saik IEI, Guessous F, Akarid K. The pro-inflammatory
- 562 cytokines in COVID-19 pathogenesis: What goes wrong? *Microb Pathog*. 2021
- 563 Apr;153:104799.
- 564 26. Kimotho J, Sein Y, Sayed S, Shah R, Mwai K, Saleh M, et al. Kinetics of naturally
- 565 induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among
- 566 SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an
- 567 observational study. *Wellcome Open Res*. 2023 Aug 17;8:350.
- 568 27. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell*. 2021
- 569 Feb;184(4):861–80.
- 570 28. Brand SPC, Ojal J, Aziza R, Were V, Okiro EA, Kombe IK, et al. COVID-19
- 571 transmission dynamics underlying epidemic waves in Kenya. *Science*. 2021 Nov
- 572 19;374(6570):989–94.

- 573 29. NIH. COVID-19 Treatment Guidelines. 2021 [cited 2024 Jun 13]. Clinical Spectrum
574 of SARS-CoV-2 Infection. Available from:
575 <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/>
- 576 30. Angyal A, Longet S, Moore SC, Payne RP, Harding A, Tipton T, et al. T-cell and
577 antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-
578 CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet
579 Microbe. 2022 Jan;3(1):e21–31.
- 580 31. Merck KGaA. Sigmaaldrich Belysa® Immunoassay Curve Fitting Software,
581 Darmstadt, Germany. 2022 [cited 2024 Apr 11]. Belysa® Immunoassay Curve Fitting
582 Software. Available from: [https://www.sigmaaldrich.com/KE/en/services/software-and-](https://www.sigmaaldrich.com/KE/en/services/software-and-digital-platforms/belysa-immunoassay-curve-fitting-software)
583 [digital-platforms/belysa-immunoassay-curve-fitting-software](https://www.sigmaaldrich.com/KE/en/services/software-and-digital-platforms/belysa-immunoassay-curve-fitting-software)
- 584 32. Gelman A, Hill J. Higher Education from Cambridge University Press. Cambridge
585 University Press; 2006 [cited 2024 Oct 28]. Data Analysis Using Regression and
586 Multilevel/Hierarchical Models. Available from:
587 [https://www.cambridge.org/highereducation/books/data-analysis-using-regression-and-](https://www.cambridge.org/highereducation/books/data-analysis-using-regression-and-multilevel-hierarchical-models/32A29531C7FD730C3A68951A17C9D983)
588 [multilevel-hierarchical-models/32A29531C7FD730C3A68951A17C9D983](https://www.cambridge.org/highereducation/books/data-analysis-using-regression-and-multilevel-hierarchical-models/32A29531C7FD730C3A68951A17C9D983)
- 589 33. R Core Team. R Foundation for Statistical Computing, Vienna, Austria. 2023 [cited
590 2024 Mar 8]. R: A language and environment for statistical computing. Available from:
591 <https://www.R-project.org/>
- 592 34. Kassambara A, Mundt F. factoextra: Extract and Visualize the Results of Multivariate
593 Data Analyses [Internet]. 2020 [cited 2024 Mar 8]. Available from: [https://CRAN.R-](https://CRAN.R-project.org/package=factoextra)
594 [project.org/package=factoextra](https://CRAN.R-project.org/package=factoextra)

- 595 35. Kolde R. pheatmap: Pretty Heatmaps [Internet]. 2019 [cited 2024 Mar 8]. (R package
596 version 1.0.12). Available from: [https://cran.r-](https://cran.r-project.org/web/packages/pheatmap/index.html)
597 [project.org/web/packages/pheatmap/index.html](https://cran.r-project.org/web/packages/pheatmap/index.html)
- 598 36. Wickham H. ggplot2: Elegant Graphics for Data Analysis [Internet]. Cham: Springer
599 International Publishing, New York; 2016 [cited 2024 Mar 8]. (Use R!). Available from:
600 <http://link.springer.com/10.1007/978-3-319-24277-4>
- 601 37. Graph pad prism programming team. Graph pad Prism, Boston, Massachusetts, USA.
602 2023 [cited 2024 Apr 11]. Prism - GraphPad. Available from:
603 <https://www.graphpad.com/features>
- 604 38. Tan AT, Linster M, Tan CW, Bert NL, Chia WN, Kunasegaran K, et al. Early
605 induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance
606 and mild disease in COVID-19 patients. Cell Rep [Internet]. 2021 Feb 9 [cited 2024 Aug
607 3];34(6). Available from: [https://www.cell.com/cell-reports/abstract/S2211-](https://www.cell.com/cell-reports/abstract/S2211-1247(21)00041-3)
608 [1247\(21\)00041-3](https://www.cell.com/cell-reports/abstract/S2211-1247(21)00041-3)
- 609 39. Rümke LW, Smit WL, Bossink A, Limonard GJM, Muilwijk D, Haas LEM, et al.
610 Impaired SARS-CoV-2 specific T-cell response in patients with severe COVID-19. Front
611 Immunol [Internet]. 2023 Apr 17 [cited 2024 Sep 13];14. Available from:
612 [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1046639/f](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1046639/full)
613 [ull](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1046639/full)
- 614 40. Garofalo E, Biamonte F, Palmieri C, Battaglia AM, Sacco A, Biamonte E, et al.
615 Severe and mild-moderate SARS-CoV-2 vaccinated patients show different frequencies of
616 IFN γ -releasing cells: An exploratory study. PLOS ONE. 2023 Feb 9;18(2):e0281444.

- 617 41. Zeng Q, Li YZ, Dong SY, Chen ZT, Gao XY, Zhang H, et al. Dynamic SARS-CoV-
618 2-Specific Immunity in Critically Ill Patients With Hypertension. *Front Immunol*
619 [Internet]. 2020 Dec 10 [cited 2024 Sep 13];11. Available from:
620 [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.596684/ful](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.596684/full)
621 1
- 622 42. Neidleman J, Luo X, George AF, McGregor M, Yang J, Yun C, et al. Distinctive
623 features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. *Cell*
624 *Rep* [Internet]. 2021 Jul 20 [cited 2024 Sep 13];36(3). Available from:
625 [https://www.cell.com/cell-reports/abstract/S2211-1247\(21\)00827-5](https://www.cell.com/cell-reports/abstract/S2211-1247(21)00827-5)
- 626 43. Takahashi M, Galligan C, Tessarollo L, Yoshimura T. Monocyte Chemoattractant
627 Protein-1 (MCP-1), Not MCP-3, Is the Primary Chemokine Required for Monocyte
628 Recruitment in Mouse Peritonitis Induced with Thioglycollate or Zymosan A. *J Immunol*
629 *Baltim Md* 1950. 2009 Sep 1;183(5):3463–71.
- 630 44. Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ. Preferential Migration of
631 Activated CD4+ and CD8+ T Cells in Response to MIP-1 α and MIP-1 β . *Science*. 1993
632 Apr 16;260(5106):355–8.
- 633 45. Jøntvedt Jørgensen M, Holter JC, Christensen EE, Schjalm C, Tonby K, Pischke SE,
634 et al. Increased interleukin-6 and macrophage chemoattractant protein-1 are associated
635 with respiratory failure in COVID-19. *Sci Rep*. 2020 Dec 10;10:21697.
- 636 46. Xu ZS, Shu T, Kang L, Wu D, Zhou X, Liao BW, et al. Temporal profiling of plasma
637 cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients.
638 *Signal Transduct Target Ther*. 2020 Jun 19;5(1):1–3.

- 639 47. Nanki T, Lipsky PE. Cutting Edge: Stromal Cell-Derived Factor-1 Is a Costimulator
640 for CD4+ T Cell Activation. *J Immunol*. 2000 May 15;164(10):5010–4.
- 641 48. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC. The Chemokine SDF-1
642 Is a Chemoattractant for Human CD34⁺ Hematopoietic Progenitor Cells and Provides a
643 New Mechanism to Explain the Mobilization of CD34⁺ Progenitors to Peripheral Blood.
- 644 49. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly
645 efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). *J Exp*
646 *Med*. 1996 Sep 1;184(3):1101–9.
- 647 50. Trifonova I, Ngoc K, Nikolova M, Emilova R, Todorova Y, Gladnishka T, et al.
648 Patterns of cytokine and chemokine expression in peripheral blood of patients with
649 COVID-19 associated with disease severity. *Int J Immunopathol Pharmacol*. 2023
650 Dec;37:039463202311636.
- 651 51. Korayem OH, Ahmed AE, Meabed MH, Magdy DM, Abdelghany WM. Genetic clues
652 to COVID-19 severity: exploring the stromal cell-derived factor-1/CXCL12 rs2839693
653 polymorphism in adult Egyptians. *BMC Infect Dis*. 2023 Oct 19;23:702.
- 654 52. Pairo-Castineira E, Rawlik K, Bretherick AD, Qi T, Wu Y, Nassiri I, et al. GWAS
655 and meta-analysis identifies 49 genetic variants underlying critical COVID-19. *Nature*.
656 2023 May;617(7962):764–8.
- 657 53. Zhang Z, Ai G, Chen L, Liu S, Gong C, Zhu X, et al. Associations of immunological
658 features with COVID-19 severity: a systematic review and meta-analysis. *BMC Infect Dis*.
659 2021 Aug 3;21(1):738.

- 660 54. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential
661 involvement of interleukin-8 (IL-8) in acute inflammation. *J Leukoc Biol.*
662 1994;56(5):559–64.
- 663 55. Dinarello C, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 Binding
664 Protein. *Front Immunol* [Internet]. 2013 Oct 8 [cited 2024 Aug 21];4. Available from:
665 <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2013.00289/full>
- 666 56. Dayer JM. Evidence for the biological modulation of IL-1 activity: The role of IL-
667 1Ra. *Clin Exp Rheumatol.* 2001 Nov 30;20:S14-20.
- 668 57. Kleynhans J, Tempia S, Wolter N, von Gottberg A, Bhiman JN, Buys A, et al. SARS-
669 CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second
670 Waves of Infections, South Africa, July 2020–March 2021. *Emerg Infect Dis.* 2021
671 Dec;27(12):3020–9.
- 672 58. Abdella S, Riou S, Tessema M, Assefa A, Seifu A, Blachman A, et al. Prevalence of
673 SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level
674 of spread during the first wave of the pandemic. *EClinicalMedicine.* 2021 May
675 1;35:100880.
- 676 59. Samandari T, Ongalo JB, McCarthy KD, Biegon RK, Madiega PA, Mithika A, et al.
677 Prevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults.
678 *J Clin Invest.* 133(13):e170011.
- 679 60. Little RJA, Rubin DB. *Statistical Analysis with Missing Data.* John Wiley & Sons;
680 2019. 462 p.
- 681

682 **Supporting information**

683 **Figure S1. Correlation matrix of 21 cytokines across all time points from 400 patients.**

684 Pearson's correlation coefficients are visualised, with red indicating positive correlations,
685 blue negative correlations, and white representing no correlation.

686 **Figure S2. Principal component analysis of the cytokines. a)** Scree-plot showing that the
687 first 3 principal components explained 62% of variability in the cytokines data for all
688 participants; **(b)** Line plots for the first 3 principal component illustrating trends over time for
689 asymptomatic participants; and **(c)** Line plots for the first 3 principal component illustrating
690 trends over time for symptomatic (mild, moderate and severe) participants.

691 **Figure S3. Cytokines loading on the first three principal components (PC1–PC3).** The
692 color scale indicates the loading value, with red indicating a higher positive loading, blue a
693 higher negative loading and light-yellow minimal loading.

694 **Figure S4. Scatter plots showing cytokine data for participants grouped by location and**
695 **clinical phenotype. (a)** Asymptomatic participants, **(b)** mild cases, **(c)** participants from
696 Kilifi, and **(d)** participants from Nairobi. Each point represents an individual's cytokine
697 measurement, allowing for a visual assessment of cytokine variability across different groups
698 based on location and clinical presentation.

699 **Table S1. Peptides Sequences.** Each entry represents a distinct peptide along with its
700 associated properties. The pooling strategy for the 10 peptide pools used is shown below.

701 **Table S2. Sample size for each peptide.** Number of participants sampled for each peptide
702 across different clinical phenotypes (asymptomatic, mild/moderate, severe) and time points
703 (Day 0, 7, 14, 28).

704 **Table S3. Associations of SARS-CoV-2 Peptides (Spike, M, NP, NSP, and ORF) with**
705 **asymptomatic, mild/moderate, and severe clinical phenotypes over time.** Tukey's

706 multiple comparisons test was used to assess differences within and between clinical

707 phenotypes across different time points. Bold p values are significant, $p < 0.05$.

708




Figure 1




Figure 2




Figure 3




Figure 4





Figure 5